Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data - European Medical Journal

This site is intended for healthcare professionals

Retraction: Talokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data

Dermatology

Author: EMJ

Citation: EMJ Dermatol. 2026.https://doi.org/10.33590/emjdermatol/IEYW6199

Original publication¹

LEO Pharma requested removal of this sponsored material due to internal compliance updates. 

Reference:

1. Humphry N. Tralokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data. EMJ Dermatol. 2025;13[Suppl 2]:2-10. https://doi.org/10.33590/emjdermatol/PRLP5831

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.